Atogepant for the Preventive Treatment of Migraine in Participants With Prior Treatment Failure: The ELEVATE Trial

被引：0
|
作者：
Pozo-Rosich, P. [1 ]
Nagy, K. [2 ]
Tassorelli, C. [3 ,4 ]
Lanteri-Minet, M. [5 ]
Sacco, S. [6 ]
Nezadal, T. [7 ]
Finnegan, M. [8 ]
Guo, H. [8 ]
Gandhi, P. [8 ]
Trugman, J. [8 ]
机构：
[1] Vall DHebron Univ Hosp, Barcelona, Spain
[2] AbbVie, Budapest, Hungary
[3] C Mondino Fdn, Headache Sci & Neurorehabil Ctr, Pavia, Italy
[4] CHU Nice, Pain Dept, Nice, France
[5] CHU Nice, FHU InovPain, Nice, France
[6] Cote Azur Univ, Nice, France
[7] Charles Univ Prague, Mil Univ Hosp, Sch Med 1, Dept Neurol, Prague, Czech Republic
[8] AbbVie, Madison, NJ USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR-137
引用
收藏
页码：212 / 213
页数：2
相关论文
共 50 条
  • [41] Preventive treatment of migraine with vasobral: a multicenter trial
    Tabeeva, G. R.
    Azimova, Yu. E.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2010, 110 (11) : 26 - 30
  • [42] Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Dodick, D. W.
    McAllister, P.
    Li, Y.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 107 - 107
  • [43] Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Dodick, D. W.
    McAllister, P.
    Li, Y.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 159 - 159
  • [44] Long-term safety and tolerability of atogepant for preventive treatment of migraine: a phase 3, 40-week, extension trial
    Klein, B.
    Miceli, R.
    Severt, L.
    McAllister, P.
    Mechtler, L.
    McVige, J.
    Diamond, M.
    Marmura, M.
    Guo, H.
    Finnegan, M.
    Trugman, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 409 - 410
  • [45] Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo- controlled, phase 3 trial
    Pozo-Rosich, Patricia
    Ailani, Jessica
    Ashina, Messoud
    Goadsby, Peter J.
    Lipton, Richard B.
    Reuter, Uwe
    Guo, Hua
    Schwefel, Brittany
    Lu, Kaifeng
    Boinpally, Ramesh
    Miceli, Rosa
    Ferreira, Rosa De Abreu
    Mccusker, Emily
    Yu, Sung Yun
    Severt, Lawrence
    Finnegan, Michelle
    Trugman, Joel M.
    LANCET, 2023, 402 (10404): : 775 - 785
  • [46] Atogepant Calcitonin gene-related peptide (CGRP) receptor antagonist Preventive treatment of migraine
    Martelletti, P.
    Cipolla, F.
    Capi, M.
    Curto, M.
    Lionetto, L.
    DRUGS OF THE FUTURE, 2020, 45 (05) : 265 - 277
  • [47] Impact of atogepant on migraine day reduction, response rate, and patient-reported outcomes in participants with episodic migraine and comorbid depressive symptoms: subgroup analysis from the ELEVATE trial
    Vernieri, F.
    Gandhi, P.
    Ashina, M.
    Seng, E.
    Lipton, R. B.
    Nagy, K.
    Liu, Y.
    Carr, K.
    Stokes, J.
    Pozo-Rosich, P.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [48] Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 106 - 107
  • [49] Atogepant improved patient-reported migraine-specific quality of life in a 12-week phase 3 (ADVANCE) trial for preventive treatment of migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    HEADACHE, 2021, 61 : 43 - 44
  • [50] Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial
    Lipton, Richard B.
    Pozo-Rosich, Patricia
    Blumenfeld, Andrew M.
    Li, Ye
    Severt, Lawrence
    Stokes, Jonathan T.
    Creutz, Lela
    Gandhi, Pranav
    Dodick, David
    NEUROLOGY, 2023, 100 (08) : E764 - E777
12345